Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening
December 18, 2024 08:00 ET
|
Medera Inc.; Keen Vision Acquisition Corporation
Innovative Technology Integration: The strategic partnership seamlessly integrates the unique ability of Novoheart’s human "Heart-in-a-Jar" to assess cardiac pump performance with Curi Bio’s...
Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing
December 10, 2024 08:00 ET
|
Medera Inc.; Keen Vision Acquisition Corporation
Innovation installed by AstraZeneca for advancing human heart-based R&D for investigational cardiovascular therapiesFeatures improved automation, environmental control, and flexible testing...
Medera and Singapore’s Cardiovascular Disease National Collaborative Enterprise Launch Asia's First Cardiac Gene Therapy Trial for Heart Failure
November 19, 2024 08:34 ET
|
Medera Inc.
Medera and Cardiovascular Disease National Collaborative Enterprise (CADENCE) announce the initiation of Asia's first cardiac gene therapy clinical trial for heart failure, with Singapore being the...